Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Company price
0.0003 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
400
Market Cap
0.15M

Momentum Score

…

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.05
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Acura Pharmaceuticals is a small specialty pharmaceutical company that develops and licenses formulations intended to deter drug abuse and tampering, including a pseudoephedrine product designed to resist extraction for illicit methamphetamine production. Long-term growth may be driven by licensing agreements, commercial adoption of abuse-deterrent products, and regulatory focus on reducing diversion. Investors may find the company attractive because it appears positioned to monetize intellectual property through partnerships rather than large manufacturing operations.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
1.56M
Revenue Per Share
0.03
Gross Profit TTM
0.04M
Debt / Equity
-
ROE
-
Net Debt
0.15M
ROCE
-351.88%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Income before tax -0.88M -1.21M -3.77M -3.84M -5.82M
Net income -0.88M -1.21M -3.77M -3.84M -5.68M
Selling general administrative 1.25M 2.55M 1.88M 2.57M 4.34M
Gross profit - 3.57M 2.66M 0.41M 2.84M
Reconciled depreciation 0.09M 0.12M 0.27M 0.28M 0.29M
Ebit - -0.76M -3.33M -3.62M -5.22M
Ebitda -0.68M -0.63M -3.04M -3.17M -4.93M
Non operating income net other - - -2.60M 0.30M 0.00M
Operating income -1.21M -0.76M -0.72M -3.92M -5.22M
Interest expense 0.20M 0.45M 0.46M 0.40M 0.00M
Tax provision 0.00M 0.00M 0.00M 0.00M -0.14M
Interest income - 0.00M 0.01M 0.17M 0.00M
Net interest income -0.20M -0.45M -0.45M -0.22M -0.59M
Income tax expense - - - - -0.14M
Total revenue 1.56M 3.57M 2.66M 0.41M 2.97M
Total operating expenses 2.78M 4.33M -3.38M 4.33M 8.06M
Cost of revenue - - - 0.00M 0.13M
Total other income expense net 0.54M - -2.60M 0.30M -0.59M
Net income from continuing ops -0.88M -1.21M -3.77M -3.84M -5.68M
Net income applicable to common shares - -1.21M -3.77M -3.84M -5.68M
Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Total assets 0.86M 1.74M 2.56M 2.15M 4.60M
Intangible assets - 0.07M 0.81M 1.02M 1.22M
Other current assets 0.15M 1.18M 1.14M 0.39M 0.35M
Total liab 0.68M 7.63M 7.30M 5.77M 4.63M
Total stockholder equity 0.18M -5.89M -4.74M -3.62M -0.03M
Other current liab 0.52M 0.70M 0.25M 0.23M 0.29M
Common stock - 0.22M 0.21M 0.21M 0.21M
Capital stock 0.65M 0.22M 0.21M 0.21M -
Retained earnings -390.08M -389.20M -388.00M -384.22M -380.38M
Other liab - - 0.23M 0.11M -
Other assets - - 0.03M 0.07M 0.14M
Cash 0.07M 0.41M 0.86M 0.09M 2.22M
Total current liabilities 0.52M 7.52M 1.07M 1.44M 4.63M
Net debt 0.15M 5.86M 5.14M 4.13M 0.47M
Short term debt - 6.16M - - 2.69M
Short long term debt - 6.16M - - 2.69M
Property plant equipment - 0.48M 0.54M 0.61M 0.68M
Total current assets 0.37M 1.18M 1.18M 0.46M 2.57M
Long term investments - - 0.03M 0.07M 0.14M
Net tangible assets - -5.96M -5.55M -4.63M -1.25M
Net receivables 0.16M 0.63M 0.03M 0.07M 0.07M
Long term debt 0.15M 0.10M 6.00M 4.22M -
Inventory - - - - 0.00M
Accounts payable 0.19M 0.66M 0.82M 1.20M 1.64M
Common stock total equity - 0.22M 0.21M 0.21M 0.21M
Retained earnings total equity - -389.20M -388.00M -384.22M -380.38M
Non currrent assets other 0.05M - 0.84M 1.08M 1.36M
Non current assets total 0.49M 0.56M 1.38M 1.69M 2.04M
Capital lease obligations 0.05M - - - -
Long term debt total - - 6.00M - -
Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Investments - - - 0.00M 0.31M
Change to liabilities - -0.37M -0.36M -0.34M 0.23M
Total cashflows from investing activities - - - - 0.31M
Net borrowings - 0.27M 1.38M 1.78M -2.76M
Total cash from financing activities 0.39M 0.27M 1.39M 1.78M 1.24M
Change to operating activities - 0.49M 0.45M -0.72M 0.29M
Net income -0.88M -1.21M -3.77M -3.84M -5.68M
Change in cash -0.35M -0.45M 0.77M -2.13M -2.96M
Begin period cash flow 0.41M 0.86M 0.09M 2.22M 5.18M
End period cash flow 0.07M 0.41M 0.86M 0.09M 2.22M
Total cash from operating activities -0.74M -0.72M -0.62M -3.91M -4.51M
Issuance of capital stock 0.00M 0.00M 0.01M 0.00M -
Depreciation 0.09M 0.12M 0.34M 0.37M 0.39M
Other cashflows from investing activities - - - - 0.31M
Change to inventory - - - 0.00M 0.10M
Change to account receivables - -0.47M -0.02M -0.07M 0.02M
Sale purchase of stock - - - - 4.00M
Other cashflows from financing activities - 0.00M 0.01M 0.00M -
Change to netincome - 0.70M 2.71M -0.08M 0.46M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change receivables - - - - 0.02M
Cash flows other operating - 0.03M 0.47M -0.02M -0.04M
Cash and cash equivalents changes - -0.45M 0.77M -2.13M -2.96M
Change in working capital 0.48M -0.34M 0.12M -0.18M 0.27M
Stock based compensation 0.06M 0.04M 0.11M - -
Other non cash items - -0.22M 0.05M -0.09M 0.10M
Free cash flow -0.74M -0.72M -0.62M -3.91M -4.51M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ACUR
Acura Pharmaceuticals Inc
-
-%
0.00 - - 0.10 0.85 0.18 -4.61
MKKGY
Merck KGaA ADR
-0.68
2.09%
31.83 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
-
-%
163.45 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR
0.38
1.77%
21.79 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.
-
-%
43.05 - 10.66 0.01 1.16 2.94 23.11

Profile*

Acura Pharmaceuticals Inc

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.

616 N. North Court, Palatine, IL, United States, 60067

847 705 7709

9

Name Title Year Born
Mr. Robert B. Jones CEO, Pres & Director 1959
Mr. Peter A. Clemens Sr. VP, CFO & Sec. 1953
Dr. Albert W. Brzeczko Ph.D. VP of Pharmaceutical Sciences of Acura Pharmaceutical Technologies, Inc. 1957
Mr. Robert A. Seiser CPA, Ph.D. VP, Treasurer & Corp. Controller 1964
Mr. Robert B. Jones CEO, President & Director 1959
Mr. Robert A. Seiser CPA, Ph.D. CFO, Senior VP, Treasurer & Corporate Controller 1964

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…